142 related articles for article (PubMed ID: 31544267)
1. Effects of lorcaserin on cardiometabolic risk factors in overweight and obese patients: A systematic review and meta-analysis.
Kuo HH; Wang KT; Lee YH; Lin PL; Liu ME; Lin CY; Liu LY
J Clin Pharm Ther; 2020 Feb; 45(1):35-44. PubMed ID: 31544267
[TBL] [Abstract][Full Text] [Related]
2. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial.
Fidler MC; Sanchez M; Raether B; Weissman NJ; Smith SR; Shanahan WR; Anderson CM;
J Clin Endocrinol Metab; 2011 Oct; 96(10):3067-77. PubMed ID: 21795446
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients.
Bohula EA; Wiviott SD; McGuire DK; Inzucchi SE; Kuder J; Im K; Fanola CL; Qamar A; Brown C; Budaj A; Garcia-Castillo A; Gupta M; Leiter LA; Weissman NJ; White HD; Patel T; Francis B; Miao W; Perdomo C; Dhadda S; Bonaca MP; Ruff CT; Keech AC; Smith SR; Sabatine MS; Scirica BM;
N Engl J Med; 2018 Sep; 379(12):1107-1117. PubMed ID: 30145941
[TBL] [Abstract][Full Text] [Related]
4. Design and rationale for the Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patients-Thrombolysis in Myocardial Infarction 61 (CAMELLIA-TIMI 61) trial.
Bohula EA; Scirica BM; Fanola C; Inzucchi SE; Keech A; McGuire DK; Smith SR; Abrahamsen T; Francis BH; Miao W; Perdomo CA; Satlin A; Wiviott SD; Sabatine MS
Am Heart J; 2018 Aug; 202():39-48. PubMed ID: 29803985
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of lorcaserin in obesity: a systematic review and meta-analysis of randomized controlled trials.
Singh AK; Singh R
Expert Rev Clin Pharmacol; 2020 Feb; 13(2):183-190. PubMed ID: 31815555
[No Abstract] [Full Text] [Related]
6. Efficacy and safety of lorcaserin in obese adults: a meta-analysis of 1-year randomized controlled trials (RCTs) and narrative review on short-term RCTs.
Chan EW; He Y; Chui CS; Wong AY; Lau WC; Wong IC
Obes Rev; 2013 May; 14(5):383-92. PubMed ID: 23331711
[TBL] [Abstract][Full Text] [Related]
7. Lorcaserin: an investigational serotonin 2C agonist for weight loss.
Hurren KM; Berlie HD
Am J Health Syst Pharm; 2011 Nov; 68(21):2029-37. PubMed ID: 22011982
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of lorcaserin: a combined analysis of the BLOOM and BLOSSOM trials.
Aronne L; Shanahan W; Fain R; Glicklich A; Soliman W; Li Y; Smith S
Postgrad Med; 2014 Oct; 126(6):7-18. PubMed ID: 25414931
[TBL] [Abstract][Full Text] [Related]
9. Lorcaserin and Renal Outcomes in Obese and Overweight Patients in the CAMELLIA-TIMI 61 Trial.
Scirica BM; Bohula EA; Dwyer JP; Qamar A; Inzucchi SE; McGuire DK; Keech AC; Smith SR; Murphy SA; Im K; Leiter LA; Gupta M; Patel T; Miao W; Perdomo C; Bonaca MP; Ruff CT; Sabatine MS; Wiviott SD;
Circulation; 2019 Jan; 139(3):366-375. PubMed ID: 30586726
[TBL] [Abstract][Full Text] [Related]
10. Multicenter, placebo-controlled trial of lorcaserin for weight management.
Smith SR; Weissman NJ; Anderson CM; Sanchez M; Chuang E; Stubbe S; Bays H; Shanahan WR;
N Engl J Med; 2010 Jul; 363(3):245-56. PubMed ID: 20647200
[TBL] [Abstract][Full Text] [Related]
11. Lorcaserin: a review of its use in chronic weight management.
Hoy SM
Drugs; 2013 Apr; 73(5):463-73. PubMed ID: 23529825
[TBL] [Abstract][Full Text] [Related]
12. Impact of lorcaserin on glycemic control in overweight and obese patients with type 2 diabetes: analysis of week 52 responders and nonresponders.
Pi-Sunyer X; Shanahan W; Fain R; Ma T; Garvey WT
Postgrad Med; 2016 Aug; 128(6):591-7. PubMed ID: 27389084
[TBL] [Abstract][Full Text] [Related]
13. Lorcaserin. In obesity: unacceptable risks.
Prescrire Int; 2014 May; 23(149):117-20. PubMed ID: 24926508
[TBL] [Abstract][Full Text] [Related]
14. Lorcaserin in Obese and Overweight Patients Taking Prohibited Serotonergic Agents: A Retrospective Analysis.
Nguyen CT; Zhou S; Shanahan W; Fain R
Clin Ther; 2016 Jun; 38(6):1498-1509. PubMed ID: 27206567
[TBL] [Abstract][Full Text] [Related]
15. [Pharmacological therapy of obesity].
Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
[TBL] [Abstract][Full Text] [Related]
16. Health-related quality of life in randomized controlled trials of lorcaserin for obesity management: what mediates improvement?
Kolotkin RL; Crosby RD; Wang Z
Clin Obes; 2017 Dec; 7(6):347-353. PubMed ID: 28815987
[TBL] [Abstract][Full Text] [Related]
17. Lorcaserin Hcl for the treatment of obesity.
Shukla AP; Kumar RB; Aronne LJ
Expert Opin Pharmacother; 2015; 16(16):2531-8. PubMed ID: 26472579
[TBL] [Abstract][Full Text] [Related]
18. The Effect of Liquid Meal Replacements on Cardiometabolic Risk Factors in Overweight/Obese Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Noronha JC; Nishi SK; Braunstein CR; Khan TA; Blanco Mejia S; Kendall CWC; Kahleová H; Rahelić D; Salas-Salvadó J; Leiter LA; Sievenpiper JL
Diabetes Care; 2019 May; 42(5):767-776. PubMed ID: 30923163
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of lorcaserin for the treatment of obesity.
Berlie HD; Hurren KM
Expert Opin Drug Metab Toxicol; 2013 Aug; 9(8):1053-9. PubMed ID: 23802690
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
